How AI Is Changing What Work Means

AI is changing work not only by speeding up familiar tasks but by letting organizations attempt work that was previously outside their reach. Personal agents can monitor email and draft replies; a financial research firm, Satrini Research, used AI to investigate possible approaches to scorpion venom. The shift raises a broader question: whether AI becomes a useful layer of everyday work, or a tool that organizations apply selectively to extend their core capabilities.

Personal agents may occupy what one speaker called a “weird third space”: less emotionally rewarding than entertainment and less dependable or indispensable than infrastructure. For utility-focused tasks, a single failure can make people reluctant to return, though it is too early to know how usage will settle. Meta’s Muse reached 10 million US downloads in 40 days, with about 2.5 million daily active users the previous week; retention was 30% after seven days and 23% after 14 days. The host cautioned against comparing it too soon with highly sticky services such as Instagram, Facebook, and Google.

Trust and setup remain practical obstacles. Researchers at security firm Clareock said they could enumerate 6,800 Muse conversation-sharing links and found content including a loan application and internal company reports. Meta temporarily disabled the sharing feature and said it was working to make it more secure. Gemini in Android Auto can combine Google services to assess a situation such as whether email and traffic indicate a user may miss a flight. The host questioned whether people will consider such integrations worth configuring, while expecting automakers to continue exploring them.

The scale of AI companies’ financial commitments underscores how much work they expect the technology to support. A Wall Street Journal report described an Anthropic prospectus draft showing an $80 billion first-half net loss and up to $750 billion in projected compute spending. The host said about $72 billion of the loss reflected stock-grant accounting, leaving an $8.7 billion operating loss; Jack Farley argued the accounting figure was not economically fundamental and could reflect convertible notes and warrants as Anthropic’s valuation rose. About $450 billion of compute spending was described as firm, uncancelable commitments over seven to 10 years; the larger figure may include conditional commitments or double ordering. Anthropic reported $16.3 billion in first-half revenue, while a reported $65 billion annual run rate and an unaudited $16.8 billion Q3 revenue figure suggested faster growth. Reuters also reported investor discomfort with a rumored $2 trillion valuation, with some preferring $1.5 trillion. OpenAI was reportedly seeking $30 billion at a $1.4 trillion valuation.

OpenAI’s acquisition of the four-year-old AI biotech startup Orchestra Bio shows one route for bringing AI into established research. Orchestra’s agents streamline lab workflows, including monitoring compound manufacturing and tracking drug trials, rather than generating candidate compounds. Its team will work on GPT Rosalind, initially released as a research preview in April and since made commercial, and Rosalind Workbench, which connects the model to scientific instruments and supports data analysis. OpenAI said the goal is to equip existing pharmaceutical and research organizations, not to build its own biotech company.

Satrini Research tested AI drug discovery because life sciences seemed underinvested and expert views of AI’s potential varied widely. A team of non-experts used Claude to design protein binders for scorpion neurotoxins, drawing on a 35-page prompt Anthropic had tested in an earlier study. About 300 sub-agents generated 318,000 candidates and selected 211 for further testing; independent tests found 17 proteins that bound four toxins. The work cost under a couple hundred thousand dollars. But binding is not venom neutralization or evidence of treatment efficacy. Wiz Plumon noted that toxin-binding proteins had been demonstrated before, and Satrini still wants to test neutralization.

The experiment also shows why faster computation does not remove the physical and institutional bottlenecks of research. DNA synthesis, protein production, toxin sourcing, and controls still had to be completed; dry-lab design took 64 hours, results took 39 days, and the work was estimated to be four to seven years from release. Anthropic has said scorpion stings affect about 1.2 million people and cause around 3,200 deaths annually, often among children with limited medical infrastructure, but this remains an early research step, not a cure. Speakers saw no near-term breakthrough that would automatically improve public sentiment toward AI: medical advances or direct dividends and shares might help, but even breakthroughs may not reverse negative perceptions.